Drug Trial Radar · NCT02373072
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Mar 2015
Primary completion
Feb 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.
Conditions
- Idiopathic Parkinson Disease
Interventions
PF-06649751Drug
Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
Trimethobenzamide HydrochlorideDrug
300mg TID, Capsules. Optional in both Cohorts.
PlaceboDrug
Subjects completing all three treatment periods will be receiving placebo once.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and proportion of subjects with Adverse Events (AEs)Time frame: Day 1 through 61
- Number of participants with vital signs data that meet criteria of potential clinical concernTime frame: Day 1 through 61
- Number of participants with ECG data that meet criteria of potential clinical concernTime frame: Day 1 through 61
- Number of participants with abnormal clinically significant laboratory measurementsTime frame: Day 1 through 61
- C-SSRS (suicidality assessment)Time frame: Day 1 through 61
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Collaborative Neuroscience Network, LLC.
Long Beach, California
MD Clinical
Hallandale, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
SNBL Clinical Pharmacology Center, Inc.
Baltimore, Maryland
Parkinson's Movement Disorder Center of Maryland
Elkridge, Maryland
Neurology Consultants of Dallas, PA
Dallas, Texas
Walnut Hill Medical Center
Dallas, Texas
Pfizer Clinical Research Unit
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.